Ultrasound-triggered bacterial nanocarrier targets pancreatic tumors in preclinical study
Published in Drugs development & discovery, Immunology, Journals, Nanomedicine.
Published October 29, 2026.
An experimental delivery platform combines engineered bacteria, nanoparticles and ultrasound to target pancreatic tumors. Xu and colleagues reported the approach in the Journal of Nanobiotechnology on October 28.
The researchers coated attenuated Salmonella VNP20009 with a polymer carrying linked 5-fluorouracil prodrugs, then added manganese carbonate nanoparticles. The bacterial component was designed to penetrate dense tumor tissue, while the coating carried the chemotherapy payload.
Ultrasound-generated reactive oxygen species cleaved sensitive chemical links to release the drug. Released manganese ions also activated the cGAS–STING immune signaling pathway, combining chemotherapy delivery with immune stimulation.
In laboratory and animal experiments, the system promoted immunogenic tumor-cell death, dendritic-cell maturation and CD8-positive T-cell infiltration. The researchers reported inhibition of orthotopic pancreatic tumor growth and limited systemic toxicity under the conditions tested.
These results support further preclinical investigation. They do not establish clinical effectiveness or long-term safety in humans, including the risks associated with administering a living bacterial carrier.